1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Viral Partnering Terms and Agreements 2010-2015

Global Viral Partnering Terms and Agreements 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 456 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in viral partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Viral partnering agreement structure
Viral partnering contract documents
Top viral deals by value
Most active viral dealmakers

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 850 links to online copies of actual viral deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of viral dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading viral deals since 2010. Deals are listed by headline value, signed by big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of viral deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all viral deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all viral partnering deals signed and announced since 2010. The chapter is organized by specific viral therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all viral partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in viral partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of viral technologies and products.

Report scope

Viral Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to viral trends and structure of deals entered into by leading companies worldwide.

Viral Partnering Terms and Agreements includes:
Trends in viral dealmaking in the biopharma industry since 2010
Analysis of viral deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of viral deal contract documents
Comprehensive access to over 850 viral deal records
The leading viral deals by value since 2010
Most active viral dealmakers since 2010

In Viral Partnering Terms and Agreements, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Viral Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 viral deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise viral rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law'Viral Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of viral deal trends since 2010
Access infectives deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between viral partner companies
Comprehensive access to over 850 links to actual viral deals entered into by the world’s biopharma companies
Indepth review of viral deals entered into by the leading fifty big pharma companies
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner viral opportunities
Uncover companies actively partnering viral opportunities

Table Of Contents

Global Viral Partnering Terms and Agreements 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral dealmaking

2.1. Introduction
2.2. Viral partnering over the years
2.3. Big pharma viral dealmaking activity
2.4. Big biotech viral dealmaking activity
2.5. Most active in viral partnering
2.6. Viral partnering by deal type
2.7. Viral partnering by industry sector
2.8. Viral partnering by stage of development
2.9. Viral partnering by technology type
2.10. Viral partnering by viral indication
2.11. Average deal terms for viral
2.11.1 Viral headline values
2.11.2 Viral upfront payments
2.11.3 Viral milestone payments
2.11.4 Viral royalty rates

Chapter 3 - Leading viral deals

3.1. Introduction
3.2. Top viral deals by value

Chapter 4 - Big pharma viral deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma viral partnering company profiles

Chapter 5 - Big biotech viral deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech viral partnering company profiles

Chapter 6 - Viral partnering contracts directory

6.1. Introduction
6.2. Viral partnering by company A-Z
6.3. Viral partnering by deal type
6.4. Viral partnering by stage of development
6.5. Viral partnering by technology type

Chapter 7 - Viral dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target

Appendices

Appendix 1 - Directory of viral deals by company A-Z 2010-2015
Appendix 2 - Directory of viral deals by deal type 2010-2015
Appendix 3 - Directory of viral deals by stage of development 2010-2015
Appendix 4 - Directory of viral deals by technology type 2010-2015
Appendix 5 - Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Recent report titles from Current Partnering

Table of figures

Figure 1: Viral partnering since 2010
Figure 2: Big pharma - top 50 - viral deals - 2010 to 2015
Figure 3: Big pharma viral deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - viral deals - 2010 to 2015
Figure 5: Big biotech viral deal frequency - 2010 to 2015
Figure 6: Active viral dealmaking activity- 2010 to 2015
Figure 7: Viral partnering by deal type since 2010
Figure 8: Viral partnering by industry sector since 2010
Figure 9: Viral partnering by stage of development since 2010
Figure 10: Viral partnering by technology type since 2010
Figure 11: Viral partnering by specific viral target since 2010
Figure 12: Viral deals with a headline value
Figure 13: Viral deal headline value distribution, US$million - discovery stage
Figure 14: Viral deal headline value distribution, US$million - preclinical stage
Figure 15: Viral deal headline value distribution, US$million - phase I stage
Figure 16: Viral deal headline value distribution, US$million - phase II stage
Figure 17: Viral deal headline value distribution, US$million - phase III stage
Figure 18: Viral deal headline value distribution, US$million - regulatory stage
Figure 19: Viral deal headline value distribution, US$million - marketed stage
Figure 20: Summary median headline value by stage of development, 2010 to 2015
Figure 21 Viral deals with upfront payment values
Figure 22: Viral deal upfront payment distribution, US$million - discovery stage
Figure 23: Viral deal upfront payment distribution, US$million - preclinical stage
Figure 24: Viral deal upfront payment distribution, US$million - phase I stage
Figure 25: Viral deal upfront payment distribution, US$million - phase II stage
Figure 26: Viral deal upfront payment distribution, US$million - phase III stage
Figure 27: Viral deal upfront payment distribution, US$million - regulatory stage
Figure 28: Viral deal upfront payment distribution, US$million - marketed stage
Figure 29: Summary median upfront payments by stage of development, 2010 to 2015
Figure 30: Viral deals with milestone payments
Figure 31: Viral deal milestone distribution, US$million - discovery stage
Figure 32: Viral deal milestone distribution, US$million - preclinical stage
Figure 33: Viral deal milestone distribution, US$million - phase I stage
Figure 34: Viral deal milestone distribution, US$million - phase II stage
Figure 35: Viral deal milestone distribution, US$million - phase III stage
Figure 36: Viral deal milestone distribution, US$million - regulatory stage
Figure 37: Viral deal milestone distribution, US$million - marketed stage
Figure 38: Viral deals with royalty rates, %
Figure 39: Viral deal royalty rate distribution, US$million - discovery stage
Figure 40: Viral deal royalty rate distribution, US$million - preclinical stage
Figure 41: Viral deal royalty rate distribution, US$million - phase I stage
Figure 42: Viral deal royalty rate distribution, US$million - phase II stage
Figure 43: Viral deal royalty rate distribution, US$million - phase III stage
Figure 44: Viral deal royalty rate distribution, US$million - regulatory stage
Figure 45: Viral deal royalty rate distribution, US$million - marketed stage
Figure 46: Summary median royalty rate by stage of development, 2010 to 2015
Figure 47: Top viral deals by value since 2010
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.